Blueprint Medicines: Q3 Earnings Snapshot

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Blueprint Medicines Corp. (BPMC) on Thursday reported a loss of $133.7 million in its third quarter.

The Cambridge, Massachusetts-based company said it had a loss of $2.20 per share.

The results surpassed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $2.39 per share.

The cancer drug developer posted revenue of $56.6 million in the period, also beating Street forecasts. Ten analysts surveyed by Zacks expected $49.6 million.

Blueprint Medicines shares have increased slightly since the beginning of the year. The stock has fallen 11% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC